Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD + cyclophosphamide + vincristine + prednisone in peripheral T-cell lymphoma (Phase II)
ChiCTR2100054588Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 1 more, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Sep 2015; status: completed.
02
Drugs
doxorubicin
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)aggressive T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2100054588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054588.